Taking the 'High' Out of Pain

February 4, 2019

Twenty years ago, there was a shift in pain management, and it became more common to prescribe opioids for chronic pain. Initially, physicians were misinformed that addiction to these medications was highly unlikely in a clinical setting, causing a shift towards prescribing opioids as the drug class of choice to treat moderate-to-severe pain. At the time, the addictive properties of opioids and their lack of proven effectiveness for treating chronic pain were not fully recognized.

Spotlight

Watermeadow Medical, an Ashfield company

Watermeadow's scientific, clinical, industry and journal experience spans almost every therapy area and a diverse international client base. Our work with both international and specialist companies of all sizes pays tribute to the breadth of experience we offer.

OTHER WHITEPAPERS
news image

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More
news image

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More

Spotlight

Watermeadow Medical, an Ashfield company

Watermeadow's scientific, clinical, industry and journal experience spans almost every therapy area and a diverse international client base. Our work with both international and specialist companies of all sizes pays tribute to the breadth of experience we offer.

Events